GlaxoSmithKline Pharma net profit rises 8 percent to Rs 116 crore in Q1

Revenue from operations rose to Rs 745 crore as against Rs 718 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing.

Published On 2022-07-26 04:00 GMT   |   Update On 2022-07-26 06:45 GMT

New Delhi: GlaxoSmithKline Pharmaceuticals on Monday said its consolidated net profit increased by 8 per cent to Rs 116 crore in the first quarter ended on June 30, 2022.The drug firm had reported a net profit of Rs 107 crore in the April-June quarter of the previous year.Revenue from operations rose to Rs 745 crore as against Rs 718 crore in the year-ago period, GlaxoSmithKline...

Login or Register to read the full article

New Delhi: GlaxoSmithKline Pharmaceuticals on Monday said its consolidated net profit increased by 8 per cent to Rs 116 crore in the first quarter ended on June 30, 2022.

The drug firm had reported a net profit of Rs 107 crore in the April-June quarter of the previous year.

Revenue from operations rose to Rs 745 crore as against Rs 718 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing.

Read also: GSK-Sanofi variant-specific COVID vaccine found effective against Omicron

"Our results reflect good momentum across general medicines and vaccines during the quarter. We have delivered strong underlying growth with market share gains across focus brands," GlaxoSmithKline Pharmaceuticals MD Sridhar Venkatesh noted..

The drug firm is a subsidiary of GSK plc, a global biopharma company.

Read also: GSK spins off consumer health business Haleon

GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company headquartered in Mumbai, Maharashtra, India. The company was founded in 1924. Its product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease and respiratory diseases.



Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News